Acute Respiratory Distress Syndrome Clinical Trial
Verified date | June 2019 |
Source | Boston Children’s Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Lung units that participate in gas exchange are known as 'recruited' lung. Patients with lung
injury suffer from a proportion of units that do not participate in gas exchange (i.e. the
derecruited lung), which results in impaired gas exchange and induces an inflammatory
cascade. The level of PEEP is often coupled to indices of oxygenation such as PaO2, PaO2 to
FIO2 ratio, or oxygen index. Currently, two strategies are widely accepted and considered
equivocal, one strategy using a lower PEEP level coupled to a certain oxygen requirement, the
other using a higher PEEP level.
The primary purpose of this study is to demonstrate the safety and efficacy of an electrical
impedance tomography (EIT) PEEP titration protocol designed to recruit collapsed lung in
children with ARDS and properly maintain lung volumes by setting an optimal PEEP level. A
safety system has been developed using the ARDSnet FIO2/PEEP High (upper threshold limit) and
Low (lower threshold limit) algorithm. Efficacy will be defined as an improvement in lung
volume as assessed by electrical impedance tomography, lung compliance and by an improvement
in markers of gas exchange. Safety will be defined as the incidence of barotrauma and
hemodynamic consequences that occur during the protocol. Those results will be compared to
incidences of barotrauma and hemodynamic compromise within the ARDS literature. Knowledge
gained from this pilot will be instrumental in developing an EIT imagine guided protocol
which will allow us to conduct future RCTs utilizing EIT technology
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 1, 2020 |
Est. primary completion date | December 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 35 Years |
Eligibility |
Inclusion Criteria: 1. All intubated and mechanically ventilated patients will be screened for the following inclusion criteria: 2. Age: Age 2 to 35 years 3. Arterial line 4. Have ARDS based on the following definition: a. The Berlin definition of ARDS36 i. Blood gas criteria: 1. Mild: PaO2/FiO2 ratio of 201-300, 2. Moderate: PaO2/FIO2 ratio of 101-200 3. Severe: PaO2/FIO2 ratio of < 100 ii. Acute onset (within 1 week) of bilateral (patchy, diffuse, or homogeneous) infiltrates consistent with pulmonary edema on chest radiograph, and iii. No evidence of left atrial hypertension 5. Conventional lung protective mechanical ventilation Chest radiograph within the first 12h after the study recruitment Exclusion Criteria: 1. Meets the above criteria for ARDS for > 72 hours 2. < 2 years of age or chest circumference < 55 cm. 3. Clinically recognized airways disease (e.g. anatomic or reactive airway disease by history, treatment or flow graphics) 4. Uncuffed endotracheal tube in place 5. Airleak 6. Congenital heart disease 7. Hemodynamically significant heart disease 8. Congenital diaphragmatic hernia 9. Pulmonary fibrosis 10. Restrictive lung disease (other than ARDS) 11. Cystic fibrosis 12. Significant pulmonary hypertension requiring treatment (eg iNO, sildenafil, flolan) 13. Severe brain injury with no intracranial pressure monitor or external ventricular drain in place 14. Extra-corporeal life support 15. Patients with unstable spinal injuries or diseases 16. Body mass index > 50 17. Active implant such as pacemaker, ICD, or diaphragm pacer 18. Skin integrity issues in the area that the belt / electrodes will be placed, such as ulcers or open wounds 19. Dressings or chest tubes that prohibit the placement of electrodes in the proper plain. 20. Open chest 21. Flail chest within the regional plain of the belt / electrodes 22. If the medical team feels that the patient is not appropriate to enroll in the study based on medical, social or emotional concerns 23. If the patient is too unstable to position the belt / electrodes and/or transition to the Draeger ventilator |
Country | Name | City | State |
---|---|---|---|
United States | Boston Children's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Children’s Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety - measured by Barotrauma | 3 days | ||
Primary | Safety - measured by Gas Exchange | 3 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A |